A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
A phase 1/2 trial of AMXI-5001:Dose Escalation Phase I in ovarian cancer, prostate cancer and pancreatic ductal adenocarcinoma, run by AtlasMedx, Incorporated, now recruiting.
Overview
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies is a phase 1/2 interventional study registered as NCT04503265 by AtlasMedx, Incorporated, with 122 participants planned, started 2020-08-12 and due to reach its primary completion in 2026-08. Interventions recorded: AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II.
Similar pages
not linked directly; found by shared links- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialEarly Phase Study of KESONOTIDE™in Participants With Solid Tumours
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.